Knocking Down TMPRSS2-ERG Fusion Oncogene by siRNA Could be an Alternative Treatment to Flutamide

Our purpose was to develop a new pharmacological approach for the treatment of prostate cancer (PCa), the most common neoplasia in men. Recently, we developed siRNA against the fusion oncogene TMPRSS2-ERG found in 50% of patients and showed an antitumoral activity in animal model. Herein, we want to...

Descripción completa

Detalles Bibliográficos
Autores principales: Urbinati, Giorgia, de Waziers, Isabelle, Slamiç, Mateja, Foussignière, Tobias, Ali, Hafiz M, Desmaële, Didier, Couvreur, Patrick, Massaad-Massade, Liliane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014457/
https://www.ncbi.nlm.nih.gov/pubmed/27023109
http://dx.doi.org/10.1038/mtna.2016.16

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014457/
https://www.ncbi.nlm.nih.gov/pubmed/27023109
http://dx.doi.org/10.1038/mtna.2016.16

Ejemplares similares